6-K 1 a6007z.htm HOLDING(S) IN COMPANY a6007z
UNITED STATES
 
SECURITIES AND EXCHANGE COMMISSION
 
Washington, D.C. 20549
 
 
FORM 6-K
 
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934
 
For the month of May 2023
 
Commission File Number: 001-41411
 
Haleon plc
(Translation of registrant’s name into English)
 
England and Wales
(Jurisdiction of Incorporation)
 
Building 5, First Floor, The Heights,
Weybridge, Surrey, KT13 0NY
(Address of principal executive offices)
 
 
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
 
 
Form 20-F ☒
 
Form 40-F ☐
 
 
 
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
 
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
 
 
 
 
 
 
 
EXHIBIT INDEX
 
Exhibit Number
 
Description
 
99.1
Press Release entitled Holding(s) in Company dated May 16, 2023
 

99.1
 

 
16 May 2023
 
HALEON PLC 
​("Haleon" or "the Company")  
​ 
TR-1: Standard form for notification of major holdings ​ 
​ 
1. Issuer Details
 
ISIN
 
GB00BMX86B70
 
 
Issuer Name
 
Haleon plc
 
 
UK or Non-UK Issuer
 
UK
 
 
2. Reason for Notification
 
An acquisition or disposal of voting rights
 
 
3. Details of person subject to the notification obligation
 
Name
 
Glaxo Group Limited
 
 
City of registered office (if applicable)
 
Brentford
 
 
Country of registered office (if applicable)
 
United Kingdom
 
 
 
Name
City of registered office
Country of registered office
GlaxoSmithKline Holdings Limited
 
Brentford
 
England
 
GlaxoSmithKline Finance plc
 
Brentford
 
England
 
 
4. Details of the shareholder
 
Name
City of registered office
Country of registered office
Vidacos Nominees Limited
 
London
 
England
 
 
5. Date on which the threshold was crossed or reached
 
12-May-2023
 
 
6. Date on which Issuer notified
 
15-May-2023
 
 
7. Total positions of person(s) subject to the notification obligation
 
 
% of voting rights attached to shares (total of 8.A)
% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)
Total of both in % (8.A + 8.B)
Total number of voting rights held in issuer
Resulting situation on the date on which threshold was crossed or reached
 
2.850000
 
0.000000
 
2.850000
 
262727073
 
Position of previous notification (if applicable)
 
5.440000
 
0.000000
 
5.440000
 
 
 
8. Notified details of the resulting situation on the date on which the threshold was crossed or reached
 
8A. Voting rights attached to shares
 
Class/Type of shares ISIN code(if possible)
Number of direct voting rights (DTR5.1)
Number of indirect voting rights (DTR5.2.1)
% of direct voting rights (DTR5.1)
% of indirect voting rights (DTR5.2.1)
GB00BMX86B70
 
262727073
 
 
2.850000
 
 
Sub Total 8.A
262727073
 
2.850000%
 
 
8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))
 
Type of financial instrument
Expiration date
Exercise/conversion period
Number of voting rights that may be acquired if the instrument is exercised/converted
% of voting rights
 
 
 
 
 
Sub Total 8.B1
 
 
 
 
8B2. Financial Instruments with similar economic effect according to (DTR5.3.1R.(1) (b))
 
Type of financial instrument
Expiration date
Exercise/conversion period
Physical or cash settlement
Number of voting rights
% of voting rights
 
 
 
 
 
 
Sub Total 8.B2
 
 
 
 
9. Information in relation to the person subject to the notification obligation
 
2. Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entities (please add additional rows as necessary)
 
 
 
Ultimate controlling person
Name of controlled undertaking
% of voting rights if it equals or is higher than the notifiable threshold
% of voting rights through financial instruments if it equals or is higher than the notifiable threshold
Total of both if it equals or is higher than the notifiable threshold
GSK plc
 
 
2.850000
 
 
2.850000%
 
GSK plc
 
GlaxoSmithKline Holdings Limited
 
2.850000
 
 
2.850000%
 
GSK plc
 
GlaxoSmithKline Finance plc
 
2.850000
 
 
2.850000%
 
GSK plc
 
Glaxo Group Limited
 
2.850000
 
 
2.850000%
 
 
10. In case of proxy voting
 
Name of the proxy holder
 
 
 
The number and % of voting rights held
 
 
 
The date until which the voting rights will be held
 
 
 
11. Additional Information
 
GSK plc is making this notification on behalf of Glaxo Group Limited, GlaxoSmithKline Finance plc and GlaxoSmithKline Holdings Limited.
 
This notification relates to the sale by Glaxo Group Limited (a wholly-owned subsidiary of GSK plc and the holder of other external minority interests of the GSK group) of a portion of its interest in Haleon plc. A separate notification has also been submitted today by GSK plc in respect of its own notification obligation.
 
Glaxo Group Limited holds its shares in Haleon plc via a custodian, Vidacos Nominees Limited (as detailed in section 4 above), which holds the legal title to those shares on Glaxo Group Limited's behalf pursuant to a custody arrangement.
 
  
12. Date of Completion
 
15-May-2023
 
 
13. Place Of Completion
 
London, England
 
 
Amanda Mellor, Company Secretary
 
 
 
 
SIGNATURE
 
 
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 
 
HALEON PLC
(Registrant)
 
Dated: May 16, 2023
By:
/s/ Amanda Mellor
 
 
Name:
Amanda Mellor
 
 
Title:
Company Secretary